Sponsors (4)
This bill lowers legal barriers to market entry and speeds patient access to lower‑cost generics and biosimilars for non‑patented uses by clarifying FDA rules, but does so at the expense of method‑of‑use patent exclusivity and with risks of legal uncertainty and reduced prescribing information that could blunt innovation incentives or complicate patient care.
Patients (especially those with chronic conditions) and health systems gain earlier access to lower‑cost generic and biosimilar medicines for indications not covered by method‑of‑use patents.
Generic and biosimilar manufacturers (including small businesses and investors) face lower litigation risk and uncertainty when seeking FDA approval and marketing products for non‑patented uses, reducing barriers to entry and encouraging competition.
The bill clarifies regulatory definitions (e.g., labeling, promotion, biosimilarity), improving predictability for FDA submissions and enforcement.
Patent owners (and potentially the broader innovation ecosystem) lose method‑of‑use exclusivity leverage, which could reduce returns that fund R&D and weaken long‑term incentives for new drug development.
Retroactive application to pending patent proceedings could strip existing patent owners of viable claims and create legal and economic uncertainty for current rights holders.
The change may incentivize manufacturers to omit certain indications from labeling to avoid infringement risk, reducing information available to prescribers and patients and potentially harming patient care.
Based on analysis of 2 sections of legislative text.
Creates a patent safe harbor shielding certain generic and biosimilar approvals, labeling, and promotion from method-of-use infringement claims when approved labeling omits the patented uses and required FDA statements are made.
Introduced December 5, 2025 by Benjamin Cline · Last progress December 5, 2025
Creates a statutory safe harbor that protects certain generic and biosimilar drug and biological applicants, and their labeling, promotion, and marketing, from infringement claims based on method-of-use patents when the applicant follows FDA pathways and omits the patented use from approved labeling and does not promote that patented use. The protection applies to ANDA applications, specified 505(b)(2) and 512(b)(2) applications, and biosimilar applications and is tied to whether the applicant made the required patent-related statements to FDA and whether labeling/promotion references the patented condition of use. The change adds new text to the patent infringement statute to define the safe harbor, incorporates existing regulatory definitions for terms like labeling and promotion, and is applied both prospectively and retroactively to past and pending conduct as of enactment.